Company profile

Advancing molecular diagnostics to the point-of-care

Our Genedrive® device is a rapid, versatile, simple-to-use and robust point-of-need molecular diagnostics platform for use in patient stratification of patients (genotyping), pathogen detection and other clinical indications such as infectious disease detection.

Our team have developed innovative tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for us in areas such as healthcare, workplace screening, travel requirements, or confirmation of antigen tests. Our focus has increasingly moved to emergency medicine, where the delivery of genetic information more quickly that possible with competitive systems is a strength of our technology. Genedrive was the very first company to deploy a commercial genetic test (Genedrive® MT-RNR1 ID Kit) into an emergency care setting.

genedrive plc is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With an historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.